US Bancorp
ORMP icon

US Bancorp’s Oramed Pharmaceuticals ORMP Stock Holding History

US Bancorp’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,000
Closed -$14K – 4166
2021
Q4 		$14K Hold
1,000
– – ﹤0.01% 3297
2021
Q3 		$22K Hold
1,000
– – ﹤0.01% 3091
2021
Q2 		$13K Buy
+1,000
New +$11.4K ﹤0.01% 3326

Other funds holding ORMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

US Bancorp's ORMP Position: Q1 2022 in Review

US Bancorp sold out of Oramed Pharmaceuticals (ORMP) in Q1 2022, closing a stake of 1,000 shares — an estimated $14K sold.

US Bancorp first reported a position in ORMP in Q2 2021 and held it in 3 quarters. The position peaked at $22K in Q3 2021. 103 funds tracked by Wall St. Rank hold ORMP as of Q1 2022.

  • US Bancorp reported no remaining Oramed Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • US Bancorp sold 1,000 Oramed Pharmaceuticals shares in Q1 2022, an estimated $14K.
  • US Bancorp first reported a position in Oramed Pharmaceuticals in Q2 2021 and held it in 3 quarters.
  • US Bancorp's Oramed Pharmaceuticals position peaked at $22K in Q3 2021.
  • 103 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2022.

Based on US Bancorp's 13F filing for Q1 2022, filed 11 May 2022.